[Skip to Navigation]
Sign In
Research Letter
November 5, 2020

Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

Author Affiliations
  • 1Burjeel Oncology-Burjeel Medical City, Abu Dhabi, United Arab Emirates
  • 2Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • 3Emirates Oncology Society, Dubai, United Arab Emirates
  • 4Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 5Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 6Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates
JAMA Oncol. 2021;7(1):129-131. doi:10.1001/jamaoncol.2020.5745

Patients with cancer, especially those receiving anticancer therapy, are at risk amidst the coronavirus disease 2019 (COVID-19) pandemic.1-3 Given the frequency of asymptomatic COVID-19,2,4,5 and presymptomatic transmission,5 symptom-based screening may inadequately triage patients to safely resume anticancer therapy.2,6

First Page Preview View Large
First page PDF preview
First page PDF preview
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words